Source - RNS
RNS Number : 7621M
GlaxoSmithKline PLC
17 October 2016
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

   

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

370.567 (personal contribution)

£17.00

370.555 (personal contribution)

£17.00

185.720 (personal contribution

£17.00

185.720 (personal contribution)

£17.00

465.257 (personal contribution)

£17.00

370.567 (matching shares)

£17.00

370.555 (matching shares)

£17.00

185.720 (matching shares)

£17.00

185.720(matching shares)

£17.00

465.257 (matching shares)

 

 

d)

Aggregated information

Aggregated volume Price

 

 

 

3155.638

£17.00

 

  

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

81.138 (personal contribution)

£17.00

81.138 (personal contribution)

£17.00

64.694 (personal contribution)

£17.00

64.694 (personal contribution)

£17.00

160.210 (personal contribution)

£17.00

160.199 (personal contribution)

£17.00

81.138 (matching shares)

£17.00

81.138 (matching shares)

£17.00

64.694 (matching shares)

£17.00

64.694 (matching shares)

£17.00

160.210 (matching shares)

£17.00

160.199 (matching shares)

 

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1224.146

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

72.533 (personal contribution)

£17.00

72.521 (personal contribution)

£17.00

47.378 (personal contribution)

£17.00

47.378 (personal contribution)

£17.00

108.850 (personal contribution)

£17.00

72.533 (matching shares)

£17.00

72.521 (matching shares)

£17.00

47.378 (matching shares)

£17.00

47.378 (matching shares)

£17.00

108.850 (matching shares) 

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

697.320

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

175.105 (personal contribution)

£17.00

70.032 (personal contribution)

£17.00

90.364 (personal contribution)

£17.00

90.352 (personal contribution)

£17.00

211.571 (personal contribution)

£17.00

211.560 (personal contribution)

£17.00

175.105 (matching shares)

£17.00

70.032 (matching shares)

£17.00

90.364 (matching shares)

£17.00

90.352 (matching shares)

£17.00

211.571 (matching shares)

£17.00

211.560 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1697.968

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

33.172 (personal contribution)

£17.00

33.172 (personal contribution)

£17.00

78.227 (personal contribution)

£17.00

78.227 (personal contribution)

£17.00

33.172 (matching shares)

£17.00

33.172 (matching shares)

£17.00

78.227 (matching shares)

£17.00

78.227 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

445.596

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

106.388 (personal contribution)

 

£17.00

156.376 (personal contribution)

 

£17.00

184.855 (personal contribution)

£17.00

184.855 (personal contribution)

£17.00

106.388(matching shares)

 

£17.00

156.376 (matching shares)

 

£17.00

184.855 (matching shares)

£17.00

184.855 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1264.948

£17.00

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

66.155 (personal contribution)

£17.00

66.142 (personal contribution)

£17.00

53.158 (personal contribution)

£17.00

53.158 (personal contribution)

£17.00

99.557 (personal contribution)

£17.00

99.557 (personal contribution)

£17.00

66.155 (matching shares)

£17.00

66.142 (matching shares)

£17.00

53.158 (matching shares)

£17.00

53.158 (matching shares)

£17.00

99.557 (matching shares)

£17.00

99.557 (matching shares)

 

 

d)

Aggregated information

Aggregated volume Price

 

 

 

875.454

£17.00

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

   

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$42.39

115.213 (personal contribution)

$42.39

115.202 (personal contribution)

$42.39

71.742 (personal contribution)

$42.39

71.742 (personal contribution)

$42.39

118.095 (personal contribution)

$42.39

118.095 (personal contribution)

$42.39

115.213 (matching shares)

$42.39

115.202 (matching shares)

$42.39

71.742 (matching shares)

$42.39

71.742 (matching shares)

$42.39

118.095 (matching shares)

$42.39

118.095 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1220.178

$42.39

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

82.083 (personal contribution)

£17.00

71.552 (personal contribution)

£17.00

71.540 (personal contribution)

£17.00

145.649 (personal contribution)

£17.00

145.649 (personal contribution)

£17.00

82.083 (matching shares)

£17.00

71.552 (matching shares)

£17.00

71.540 (matching shares)

£17.00

145.649 (matching shares)

£17.00

145.649 (matching shares)

 

 

d)

Aggregated information

Aggregated volume Price

 

  

1032.946

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

49.436 (personal contribution)

£17.00

48.598 (personal contribution)

£17.00

89.112 (personal contribution)

£17.00

49.436 (matching shares)

£17.00

48.598 (matching shares)

£17.00

89.112 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

374.292

£17.00

  

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$42.39

46.628 (personal contribution)

$42.39

46.628 (personal contribution)

$42.39

37.123 (personal contribution)

$42.39

37.123 (personal contribution)

$42.39

83.585 (personal contribution)

$42.39

83.585 (personal contribution)

$42.39

46.628 (matching shares)

$42.39

46.628  (matching shares)

$42.39

37.123  (matching shares)

$42.39

37.123  (matching shares)

$42.39

83.585  (matching shares)

$42.39

83.585  (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

 

 

669.344

$42.39

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, Pharmaceuticals R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.00

146.682 (personal contribution)

£17.00

146.671 (personal contribution)

£17.00

105.324 (personal contribution)

£17.00

105.324 (personal contribution)

£17.00

171.329 (personal contribution)

£17.00

171.329 (personal contribution)

£17.00

146.682 (matching shares)

£17.00

146.671  (matching shares)

£17.00

105.324 (matching shares)

£17.00

105.324 (matching shares)

£17.00

171.329 (matching shares)

£17.00

171.329 (matching shares)

 

d)

Aggregated information

Aggregated volume Price

 

 

  

1693.318

£17.00

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

n/a

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHKDLFFQBFBFBF

Related Charts

GlaxoSmithKline (GSK)

+17.25p (+1.18%)
delayed 18:15PM